Teva announced that the FDA has approved QNASL (beclomethasone dipropionate) Nasal Aerosol, a non-aqueous, “dry” nasal aerosol corticosteroid for the treatment of seasonal and perennial allergic rhinitis in adults and adolescents >12 years of age.

The safety and efficacy of QNASL Nasal Aerosol was demonstrated in four, Phase III randomized, double-blind, parallel-group, multicenter, placebo-controlled clinical trials. In these trials, patients received QNASL 320mcg once daily administered as two sprays in each nostril. The product is expected to be available by prescription in April 2012.

QNASL is an intranasal corticosteroid administered as a non-aqueous or “dry” spray delivered by hydrofluoroalkane (HFA).

For more information call (215) 591-3000 or visit